{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T18:47:24Z","timestamp":1726080444276},"publisher-location":"Cham","reference-count":55,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030410070"},{"type":"electronic","value":"9783030410087"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-41008-7_16","type":"book-chapter","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T16:08:46Z","timestamp":1587053326000},"page":"287-293","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal Toxicity"],"prefix":"10.1007","author":[{"given":"Maen","family":"Abdelrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"issue":"7","key":"16_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221.","journal-title":"PLoS One"},{"issue":"3","key":"16_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"2","key":"16_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160\u20139.","journal-title":"Am J Nephrol"},{"issue":"2","key":"16_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68(2):287\u201391.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"16_CR5","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","volume":"22","author":"B Thajudeen","year":"2015","unstructured":"Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22(3):e84\u20137.","journal-title":"Am J Ther"},{"issue":"4","key":"16_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","volume":"32","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Gueutin V, Gharbi C, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32(4):769\u201373.","journal-title":"Investig New Drugs"},{"issue":"11","key":"16_CR7","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/ndt\/gfh485","volume":"19","author":"MR Clarkson","year":"2004","unstructured":"Clarkson MR, Giblin L, O\u2019Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19(11):2778\u201383.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"16_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541\u20137.","journal-title":"Immunity"},{"issue":"6204","key":"16_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","volume":"345","author":"HS Kuehn","year":"2014","unstructured":"Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623\u20137.","journal-title":"Science"},{"key":"16_CR10","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1111\/j.1523-1755.2005.09423.x","volume":"94","author":"G Zheng","year":"2005","unstructured":"Zheng G, Wang Y, Mahajan D, et al. The role of tubulointerstitial inflammation. Kidney Int Suppl. 2005;94:S96\u2013100.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"16_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4049\/jimmunol.1400497","volume":"194","author":"K Jaworska","year":"2015","unstructured":"Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194(1):325\u201333.","journal-title":"J Immunol"},{"issue":"6","key":"16_CR12","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/ndt\/gfl818","volume":"22","author":"Y Waeckerle-Men","year":"2007","unstructured":"Waeckerle-Men Y, Starke A, Wuthrich RP. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant. 2007;22(6):1527\u201336.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"16_CR13","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1681\/ASN.2006050418","volume":"17","author":"Z Spanou","year":"2006","unstructured":"Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17(10):2919\u201327.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"16_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nm.2621","volume":"18","author":"VK Kuchroo","year":"2012","unstructured":"Kuchroo VK, Ohashi PS, Sartor RB, Vinuesa CG. Dysregulation of immune homeostasis in autoimmune diseases. Nat Med. 2012;18(1):42\u20137.","journal-title":"Nat Med"},{"issue":"3","key":"16_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9(3):411\u20137.","journal-title":"Clin Kidney J"},{"issue":"2","key":"16_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.smim.2011.01.014","volume":"23","author":"L Klareskog","year":"2011","unstructured":"Klareskog L, Malmstrom V, Lundberg K, Padyukov L, Alfredsson L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol. 2011;23(2):92\u20138.","journal-title":"Semin Immunol"},{"issue":"7","key":"16_CR17","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2010.06.015","volume":"141","author":"JA Todd","year":"2010","unstructured":"Todd JA. D\u2019oh! genes and environment cause Crohn\u2019s disease. Cell. 2010;141(7):1114\u20136.","journal-title":"Cell"},{"issue":"11","key":"16_CR18","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69(11):1751\u201363.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"16_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","volume":"17","author":"M Lidar","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17(3):284\u20139.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"16_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211\u20132.","journal-title":"N Engl J Med"},{"issue":"3","key":"16_CR21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","volume":"89","author":"JM Kidd","year":"2016","unstructured":"Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016;89(3):720.","journal-title":"Kidney Int"},{"issue":"2","key":"16_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.","journal-title":"Immunity"},{"key":"16_CR23","unstructured":"Umut Selamet AZ, Lakhani LS, Workeneh B, Lahoti A, Tchakarov A, Glass WF, Abudayyeh A. Biopsy proven nephrotoxicity of immune checkpoint inhibitors: MD Anderson Cancer Center Experience. Paper presented at: American Society of Nephrology Kidney Week; November 3 2017, 2017."},{"issue":"2","key":"16_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168(2):121\u201330.","journal-title":"Ann Intern Med"},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21\u20139.","journal-title":"Eur J Cancer"},{"key":"16_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2047-1440-3-10","volume":"3","author":"E Dahlke","year":"2014","unstructured":"Dahlke E, Murray CA, Kitchen J, Chan AW. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res. 2014;3:10.","journal-title":"Transplant Res"},{"issue":"19","key":"16_CR27","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","volume":"32","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32(19):e69\u201371.","journal-title":"J Clin Oncol"},{"issue":"9","key":"16_CR28","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J Jr, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"16_CR29","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/ajt.13786","volume":"16","author":"CL Boils","year":"2016","unstructured":"Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant. 2016;16(8):2496\u20137.","journal-title":"Am J Transplant"},{"issue":"6","key":"16_CR30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","volume":"27","author":"L Spain","year":"2016","unstructured":"Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"16_CR31","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/ajt.13711","volume":"16","author":"T Alhamad","year":"2016","unstructured":"Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16(4):1332\u20133.","journal-title":"Am J Transplant"},{"issue":"1","key":"16_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ki.2010.97","volume":"78","author":"A Starke","year":"2010","unstructured":"Starke A, Lindenmeyer MT, Segerer S, et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int. 2010;78(1):38\u201347.","journal-title":"Kidney Int"},{"issue":"4","key":"16_CR33","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1600-6143.2011.03451.x","volume":"11","author":"LV Riella","year":"2011","unstructured":"Riella LV, Watanabe T, Sage PT, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011;11(4):832\u201340.","journal-title":"Am J Transplant"},{"issue":"12","key":"16_CR34","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/01.tp.0000250757.69384.79","volume":"82","author":"J Dudler","year":"2006","unstructured":"Dudler J, Li J, Pagnotta M, Pascual M, von Segesser LK, Vassalli G. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation. 2006;82(12):1733\u20137.","journal-title":"Transplantation"},{"key":"16_CR35","unstructured":"Noha Abdel-Wahab AA, Mohsin Shah M, Johnson DH, Suarez-Almazor ME, Diab A. The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: a systematic review of the literature. Paper presented at: SITC2018."},{"issue":"1","key":"16_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):106.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"16_CR37","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376\u201384.","journal-title":"Cancer"},{"issue":"15_suppl","key":"16_CR38","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1200\/jco.2009.27.15_suppl.9559","volume":"27","author":"N Janus","year":"2009","unstructured":"Janus N, Oudard S, Beuzeboc P, et al. Prevalence of renal insufficiency in cancer patients: data from the IRMA-2 study. J Clin Oncol. 2009;27(15_suppl):9559.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16_CR39","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","volume":"103","author":"N Janus","year":"2010","unstructured":"Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815\u201321.","journal-title":"Br J Cancer"},{"issue":"4","key":"16_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF02850082","volume":"22","author":"E Dogan","year":"2005","unstructured":"Dogan E, Izmirli M, Ceylan K, et al. Incidence of renal insufficiency in cancer patients. Adv Ther. 2005;22(4):357\u201362.","journal-title":"Adv Ther"},{"issue":"3","key":"16_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1758834016679942","volume":"9","author":"C Mazza","year":"2017","unstructured":"Mazza C, Escudier B, Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2017;9(3):171\u201381.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"16_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.urology.2010.11.050","volume":"77","author":"D Canter","year":"2011","unstructured":"Canter D, Kutikov A, Sirohi M, et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology. 2011;77(4):781\u20135.","journal-title":"Urology"},{"issue":"10","key":"16_CR43","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","volume":"108","author":"C Coppin","year":"2011","unstructured":"Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556\u201363.","journal-title":"BJU Int"},{"issue":"7","key":"16_CR44","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381\u20135.","journal-title":"Cancer Res"},{"issue":"19","key":"16_CR45","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"2","key":"16_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","volume":"41","author":"N Murakami","year":"2017","unstructured":"Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer. 2017;41(2):100\u201310.","journal-title":"Curr Probl Cancer"},{"issue":"14","key":"16_CR47","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"3","key":"16_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405\u201315.","journal-title":"Lancet Oncol"},{"issue":"4","key":"16_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","volume":"19","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19(4):451\u201360.","journal-title":"Lancet Oncol"},{"key":"16_CR50","doi-asserted-by":"crossref","unstructured":"Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76\u201383.","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"issue":"7","key":"16_CR51","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","volume":"27","author":"G Manson","year":"2016","unstructured":"Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27(7):1199\u2013206.","journal-title":"Ann Oncol"},{"key":"16_CR52","doi-asserted-by":"crossref","unstructured":"Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011;29(15).","DOI":"10.1200\/jco.2011.29.15_suppl.2505"},{"issue":"3","key":"16_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","volume":"23","author":"C Pages","year":"2013","unstructured":"Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23(3):227\u201330.","journal-title":"Melanoma Res"},{"issue":"2","key":"16_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","volume":"376","author":"R Barnett","year":"2017","unstructured":"Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med. 2017;376(2):191\u20132.","journal-title":"N Engl J Med"},{"issue":"28","key":"16_CR55","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Experimental Medicine and Biology","Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-41008-7_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T05:10:27Z","timestamp":1615266627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-41008-7_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030410070","9783030410087"],"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-41008-7_16","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"17 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}